 Adagene Inc NASDAQ: ADAG has entered into a clinical trial collaboration and supply agreement with Merck Co Inc NYSE: MRK. The agreement includes two clinical studies to evaluate Adagenes anti-CTLA-4 monoclonal antibody mAb candidates, ADG116 and ADG126, in combination with Mercks Keytruda pembrolizumab, for patients with advancedmetastatic solid tumors. 